1. Scrip
  2. >>Focus On Asia

Invida CEO John Graham On Commercializing Products In Asia: An Interview With PharmAsia News (Part 1 of 2)

 
• By Joshua Berlin

On the sidelines of the JP Morgan Healthcare Conference, Graham talks about Menarini’s acquisition of Invida, plans for expansion in China and India, and his favorite non-BRIC emerging markets.

SAN FRANCISCO – Invida Group Pte. Ltd. CEO John Graham has helped build a company focused on commercializing differentiated products in Asian markets primarily through partnerships with small and medium-sized firms without a commercial presence in Asia. Based in Singapore, Invida has a commercial footprint in Australia, China, Hong Kong, India, Indonesia, Malaysia, New Zealand, South Korea, Taiwan, Thailand, the Philippines and Vietnam, with more than 3,500 employees providing support throughout the commercial value chain from regulatory approval to product launch to lifecycle management.

The company markets more than 70 brands, including pharmaceuticals, medical devices and consumer health products, focusing on dermatology, primary care,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.